BioCryst Pharmaceuticals (BCRX) Scheduled to Post Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is scheduled to issue its quarterly earnings data before the market opens on Monday, May 6th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The firm had revenue of $93.40 million for the quarter, compared to analysts’ expectations of $89.19 million. On average, analysts expect BioCryst Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioCryst Pharmaceuticals Trading Down 0.7 %

Shares of BCRX opened at $4.45 on Friday. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.96. The firm has a market capitalization of $918.17 million, a price-to-earnings ratio of -3.77 and a beta of 1.96. The firm’s 50-day moving average price is $4.93 and its 200-day moving average price is $5.47.

Analysts Set New Price Targets

Separately, Needham & Company LLC reiterated a “buy” rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $13.83.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.